Objective:准确识别缺血半影区，是急性临床中风的靶目标，对于识别可能从再灌注治疗中获益的患者至关重要。因此，我们旨在验证磁共振成像（MRI） mismatch– 基于半影区检测和定量15O-PET，急性中风的半影区检测的金标准。

Methods: 10名患者（A组）接受了急性或亚急性中风，进行 perfusion-weighted (PW)/ diffusion-weighted MRI 和连续的定量15O-PET 在中风发病后48小时内。半影区由15O-PET脑血流 (CBF), 氧摄取率, 和氧代谢来定义。半影区被定义为一系列已建立的 PW 参数 (如, 时间-峰值 (Tmax)) 来验证半影区检测的广泛范围。验证使用基于体素的受体-操作-特征曲线分析。基于定量15O-PET CBF 定义的半影区的验证，是为了比较原因，在中风发病后48小时内测量了23名患者（B组）。

Results: Tmax (area-under-the-curve = 0.88) 在检测半影区组织到48小时中风发病后表现最好。最优阈值来区分半影区和大脑皮层 (Tmax >5.6秒) 有高灵敏度和高特异性（>80%）。

Interpretation: 最佳 PW 参数 Tmax 检测缺血半影区阈值的性能是优秀的。Tmax >5.6秒– 基于半影区的检测是可靠的，可以在临床中快速和准确地检测半影区组织，避免再灌注治疗的阈值可以指导治疗决策，直到目前的时间窗口。
(CBF) with an elevated oxygen extraction fraction (OEF) accounting for a proportionally preserved or even normal cerebral metabolic rate of oxygen (CMRO₂).4,6–11 Although PET is still considered the gold standard for penumbra detection in acute human stroke,2,3 it requires complex logistics and is difficult to perform in the clinical setting. Therefore, simpler and wider applicable imaging modalities to detect penumbral tissue in acute ischemic stroke, such as the mismatch concept in magnetic resonance imaging (MRI), have been introduced.12,13 Since the first operational definition of the MRI-based “mismatch” between diffusion-weighted (DWI) and perfusion-weighted (PWI) MRI as a surrogate of penumbra in acute stroke,14 the mismatch concept is still challenged by the accurate PWI-based discrimination of penumbral from oligemic tissue to select candidates for therapeutic interventions.

To optimize the detection of tissue at risk of infarction based on PWI, various perfusion maps and their corresponding thresholds have been investigated. In the clinical setting, however, the choice of the best PW map and its optimal upper penumbral flow threshold is still a matter of debate.15 To address this controversy, and because recent stroke studies have proven for the first time the clinical benefit of mismatch-based thrombectomy 6 to 24 hours after stroke onset (DEFUSE-3, DAWN),16,17 it is important to validate PW parameters with full quantitative ¹⁵O-PET to make this imaging procedure a reliable tool to detect salvageable tissue in acute stroke. Several previous studies validated PW maps in terms of tissue at risk detection in acute stroke against absolute or relative CBF measures (PET, single photon emission computed tomography, and xenon computed tomography [Xe-CT]).15 However, flow measures alone, even though established, are only surrogate markers to define penumbral tissue. Therefore, we validated the mismatch concept against the classic concept of penumbra as defined by full quantitative ¹⁵O-PET measures of blood flow and oxygen metabolism (PET-CBF, -OEF, and -CMRO₂). In addition, to give a more complete image of the optimal PWI maps and thresholds to detect the penumbral flow threshold, we also validated PWI map performance based on our bigger quantitative PET-CBF group for comparative reasons.

To help clinicians assess the tissue at risk of infarction with high accuracy, we validated for the first time a wide range of PWI maps up to 48 hours after stroke against full quantitative ¹⁵O-PET in terms of (1) their threshold independent performance to detect the penumbral flow threshold, (2) their best threshold to optimize the detection of the penumbral flow threshold, and (3) their performance to detect the penumbral flow threshold up to 48 hours after stroke onset.

Patients and Methods
Patients
This study includes 2 different groups of patients with acute and subacute ischemic hemispheric stroke. Group A was measured with full quantitative ¹⁵O-PET to evaluate CBF, cerebral blood volume (CBV), OEF, and CMRO₂; group B was measured with quantitative ¹³O-PET to evaluate CBF. These patients underwent acute consecutive MRI and PET within 48 hours of symptom onset as part of a prospective research protocol. The comparative PET-MRI patient sample (PET-MRI validation group) was measured on the same scanners with the same procedures and sequences. The patients in group A were studied from 2004 to 2017. Four patients have previously been reported, but these studies either had another focus or were methodically different or both.18–21,29 The patients in group A were selected from our PET-MR validation group based on full quantitative ¹⁵O-PET CBF, OEF, and CMRO₂ measured within 48 hours of stroke onset. The patients in group B were studied from 2003 to 2016. All have previously been reported, but these studies either had another focus or were methodically different or both.18,19,21–23 The patients in group B were selected from our PET-MR validation group based on quantitative ¹⁵O-PET CBF measured within 48 hours of stroke onset. The patients in group B were analyzed in line with group A and included in the study for comparative reasons. An experienced stroke neurologist supervised the patients during the whole procedure according to our stroke unit standards, and only clinically stable patients were included in the study. Time between both imaging modalities was kept as short as possible (for time intervals, see clinical data in the Results section), and patients with clinical changes in National Institutes of Health Stroke Scale (NIHSS) >2 during and between both imaging procedures were excluded. Patients receiving thrombolytic therapy or thrombectomy did not receive PET after MRI and were not included in the study. The study was approved by the local ethics committee of the University of Cologne, Germany. All patients gave written informed consent in accordance with the ethical standards of the Helsinki Declaration of 1975 and its later amendments.

MRI and PET Image Acquisition
MRI was performed in both groups on a 1.5T whole-body scanner (Intera Master; Philips, Best, the Netherlands). Dynamic susceptibility contrast (DSC) PWI was performed in an axial direction (20 slices, slice thickness = 6mm, interslice gap = 0.6mm, field of view = 23cm), and multishot 3-dimensional (3D) T₂*-weighted gradient echo planar imaging (EPI) sequences (principles of echo shifting using a train of observations; effective echo time [TE] = 25 milliseconds, flip angle = 9°, EPI factor = 17, matrix = 64 × 51, resulting voxel size = 3.6 × 3.6 × 6mm) were used. The DSC PW protocol
included 60 measurements at intervals of 1.3 seconds after standardized intravenous injection of 20ml of gadolinium-diethylenetriaminepentaacetic acid (Magnevist, Schering AG; power-injector flow rate 10ml/s, followed by 20ml saline). DWI used single shot spin-echo EPI (TE = 96 milliseconds, repetition time = 3,560 milliseconds, flip angle = 90°, matrix = 256 × 256, field of view [FoV] = 230 × 230, b = 0 and b = 1,000, pixel size = 0.9 × 0.9mm², slice thickness = 6mm, interslice gap = 0.6mm), and T1 fast field echo (FFE) sequence was TE = 1.8 milliseconds, TR = 145 milliseconds, flip angle = 80°, matrix = 256 × 256, FoV = 230 × 230, pixel size = 0.9 × 0.9mm², slice thickness = 6mm, interslice gap = 0.6mm.

PET was performed in a resting state on an ECAT EXACT HR scanner (CTI; Siemens, Erlangen, Germany). Emission scans were performed in a 2- and 3D data acquisition mode providing 47 contiguous 3mm slices of 5mm full width at half maximum (FWHM) in plane reconstructed resolution. The PET investigations of group A consisted of a total of 3 studies, with the complete study lasting approximately 30 to 40 minutes. CBF was measured with an intravenous bolus of 60mCi (2.2GBq) 15O-H2O. OEF was measured with 15O-O2 gas inhaled by a deep single breath of 50mCi (1.85GBq) followed by breath holding of approximately 10 to 15 seconds. CBV was measured by inhalation of 50mCi (1.85GBq) 15O-CO allowing equilibrium before PET scanning was started. For both 15O-H2O and 15O-O2 measures, an arterial input function (AIF) was measured by continuous arterial blood sampling (radial artery) with an automated blood-sampling system. For the 15O-CO studies, manually drawn blood samples were measured in a well counter after equilibrium between brain and blood activities was reached. From these measures, regional values of CBF, CBV, OEF, and CMRO2 were generated on a pixel-by-pixel basis as described previously. The PET investigations of group B consisted of 1 study of quantitative PET-CBF, with the complete study lasting approximately 10 minutes.

All further postprocessing and analysis of the data from group B, which validated PWI maps based only on the established PET-CBF penumbra threshold, were performed in line with group A.

**MRI Postprocessing**

Postprocessing of the MRI DSC PW raw images was performed by using our in-house software to realign all raw Digital Imaging and Communications in Medicine (DICOM) DSC PW images to correct for movement artifacts. Then we used the research software PMA (v5.0) to generate (1) the non-deconvolved PW maps time to peak (TTP), bolus arrival time (BAT), bolus end time (BET), FWHM, first moment (FM) without delay correction (DC), FM with DC, CBV of the curve of the tissue contrast time curve (CBVCTC), maximum concentration (Cmax), negative enhancement integral (NEI), normalized signal drop (dS/S) and maximum slope (MS) of the tissue response curve before deconvolution; and (2) the deconvolved PW maps CBF, CBV, mean transit time (MTT), and time to maximum (Tmax) (Fig 1). Deconvolved PW maps were derived from the deconvolved tissue response curve using the nonparametric standard singular value decomposition method. Deconvolution was performed with a nondistorted AIF defined by 5 to 10 voxels manually chosen from the contralateral proximal M1 segment of the middle cerebral artery (MCA). For a detailed description of these maps calculated with PMA, see the study by Leiva-Salinas and colleagues.

Normalization of the nondeconvolved PW maps (eg, to remove variability due to injection timing and arrival time differences of the bolus contrast agent) was performed in line with previous studies. For this purpose, the mean value of a region of interest (ROI) covering the MCA territory contralateral to the affected hemisphere, in a slice including the basal ganglia, was determined. All temporal PWI parameters (eg, TTP, FM, BAT, BET, and FWHM) were normalized by subtraction of the mean contralateral ROI value (eg, TTP_absolute – TTP_ROI). Normalization of non-deconvolved surrogates of CBF and CBV (eg, Cmax, MS, and CBVCTC) were expressed as the ratio to the contralateral mean ROI value (eg, Cmax_absolute/Cmax_ROI).

**MRI and PET Image Analysis**

All PET and MR images were analyzed with a multimodal-imaging tool VINCI (Max Planck Institute for Neurological Research, Cologne, Germany). To match spatial resolution, PET images were resized to the PW MR images, which were previously filtered (gauss 3D filter) to match the FWHM of the PET images. All PET and MR images were then realigned by a fully automated algorithm. For each patient, a 3D grey matter brain mask based on the individual T1 image was automatically created and manually corrected using VINCI. The grey matter masks were resliced to the PW MR image dimensions. Then a direct voxel-based analysis of the PET and MR images was performed within this individual 3D brain mask including the cortex (grey matter) of the ischemic hemisphere. The voxel values from the coregistered PET-CBF, -CBV, -OEF, -CMRO2 and PW-MRI maps (group A) and PET-CBF and PW-MRI maps (group B) were used for a direct voxel-based analysis. PET CBV voxels >8.0ml/100g/min were excluded as artifactual (group A). Voxels within the infarcted tissue without contrast bolus arrival during PWI scanning were excluded from further analysis. To prevent our analysis from being biased by necrosis or established reperfusion (very low OEF), we excluded all voxels with OEF

---

**References**

1. Heiss and colleagues
2. Sobesky and colleagues
3. PET investigations of group B consisted of 1 study of quan-
4. tative PWI maps (group A) and PET-CBF and PW-MRI maps (group B) were used for a direct voxel-based analysis. PET CBV voxels >8.0ml/100g/min were excluded as artifactual (group A). Voxels within the infarcted tissue without contrast bolus arrival during PWI scanning were excluded from further analysis. To prevent our analysis from being biased by necrosis or established reperfusion (very low OEF), we excluded all voxels with OEF

---

**June 2019 877**
below the minimum value of the individual contralateral OEF values (group A). The remaining voxels were used for further analysis.

For analysis of group A, we chose previously validated PET thresholds which fulfilled the classic criteria for penumbra with reduced CBF, compensatory increased OEF, and relatively preserved CMRO\(_2\): (1) established CBF penumbra threshold <20ml/100g/min\(^2\), (2) significantly elevated OEF of more than the individual mean contralateral OEF plus 2 standard deviations (OEF > mean OEF\(_{contra} + 2\ SD\))\(^{38}\), and (3) viable tissue threshold CMRO\(_2\) > 64µmol/100g/min (equates to >1.5ml/100g/min).\(^{4,7,8,39}\) For analysis of group B, we chose the established PET-CBF penumbra threshold <20ml/100g/min.\(^{2,3,8}\)
**Statistical Image Analysis**

The accuracy of the PWI maps to detect the penumbral flow threshold as defined by full quantitative PET was determined by a receiver operating characteristic (ROC) curve analysis. The previously defined classic $^{15}$O-PET–based penumbra criteria CBF < 20ml/100g/min, OEF > mean OEFcontr + 2 SD, and CMRO$_2$ > 64μmol/100g/min were used as a discriminator to define tissue as penumbral or nonpenumbral in group A. The established PET-CBF penumbra threshold of <20ml/100g/min was used as a discriminator in group B. The ROC curve analysis provides 2 important measures, the area under the curve (AUC) and the equal sensitivity and specificity threshold (ESST)-based cutoff thresholds. The AUC represents a threshold independent accuracy measure of penumbral flow threshold detection. The ESST-based cutoff threshold represents the optimal threshold of the PWI maps to detect the penumbra threshold as defined by the stringent penumbral PET criteria. The ROC curve analysis was performed separately for each patient identifying the AUC and the ESST-based cutoff thresholds for each PWI map. The median and interquartile range (IQR) of the AUC and the median and bootstrapped confidence interval (CI) of the ESST-based cutoff thresholds as well as their sensitivity and specificity values were calculated. To test the ROC curve–derived optimal penumbral flow Tmax and TTP thresholds, we calculated bias-corrected and accelerated (BCa) bootstrapped 95% CIs (iterations = 1,000; random number seed = 978), adjusted for possible bias and skewness in the bootstrap distribution.

We tested for differences of PWI map performance (AUC) between the PW maps. The differences of the AUC were tested by a repeated-measures analysis of variance on ranks and a post hoc analysis Student–Newman–Keuls procedure for multiple comparisons at a corrected type I error level of 0.05. Data were analyzed with SigmaPlot 12.5 (Sysstat, 2012), R software (v3.5.0) and MedCalc (v18.11).

**Results**

**Clinical Data**

In this comparative study 2 groups were analyzed: group A (PET-CBF, -OEF, and -CMRO$_2$) included 10 patients (6 women, 4 men) with acute or subacute ischemic stroke (median age = 66 years [IQR = 56–74], median NIHSS = 12 [IQR = 4–14]). Consecutive PET and MRI were performed within 48 hours (median time = 10 hours [IQR = 4–35]) after stroke onset. Five patients were measured within 12 hours (time = 4 hours [IQR = 2.9–4.9]), and 5 patients measured between 12 to 48 hours (time = 35 hours [IQR = 17.8–42]). The median time delay between PET and MRI was 116 minutes (IQR = 100–150). Stenosis of the internal carotid artery (ICA) or MCA was present in 6 patients ipsilateral and in 2 patients contralateral to the infarct (Table 1). Group B (PET-CBF) included 23 patients (12 women, 11 men) with acute or subacute ischemic stroke (median age = 56 years [IQR = 42–63], median NIHSS = 13 [IQR = 7–18]). Consecutive PET and MRI was performed within 48 hours (median time = 12 hours [IQR = 7–25]) after stroke onset. Ten patients were measured within 12 hours (time = 5.8 hours [IQR = 3.5–7]), and 13 patients were measured between 12 to 48 hours (time = 24 hours [IQR = 19.8–31.5]). The median time delay between PET and MRI was 67 minutes (IQR = 51–138). Stenosis of the ICA or MCA was present in 10 patients ipsilateral and in 4 patients contralateral to the infarct.

**ROC Curve Analysis**

All patients exhibited penumbral tissue on PET and PWI up to 48 hours after ischemic stroke (Fig 2). Accuracy of the PWI maps to detect penumbral tissue, as defined by the ROC curve analysis, varied considerably between the different maps and was best for deconvolved Tmax in group A and best for deconvolved Tmx and nondeconvolved TTP and FM without DC in group B. The ROC curve analysis was performed separately for each patient and PWI modality. The AUC values, which indicate the threshold independent performance to detect penumbral flow, were pooled among the 10 patients (group A) and 23 patients (group B) for every single PW map. The best performing PW map based on the AUC of the penumbra gold standard PET group (group A) was deconvolved Tmax (AUC = 0.88, IQR = 0.78–0.91), which performs significantly better ($p < 0.05$) than other established deconvolved PW maps, for example, CBF (AUC = 0.70, IQR = 0.64–0.85) and MTT (AUC = 0.69, IQR = 0.62–0.79) as well as nondeconvolved PW maps, for example, TTP (AUC = 0.83, IQR = 0.74–0.88) and FM without DC (AUC = 0.81, IQR = 0.74–0.87; Table 2).

The optimal pooled thresholds to detect penumbral flow based on the ESST of the penumbra gold standard PET group (group A) were for the best deconvolved measure Tmx > 5.6 seconds (95% CI = 4.6–6.1) with a sensitivity of 81% (IQR = 70–83%) and specificity of 81% (IQR = 71–83%) and for the best nondeconvolved measures TTP > 3.8 seconds (95% CI = 3.7–4.4) with a sensitivity of 77% (IQR = 68–81%) and a specificity of 77% (IQR = 67–82%). In the bigger PET-CBF group (group B), the optimal penumbral flow thresholds were for deconvolved Tmx > 6.0 seconds (95% CI = 4.9–6.9) with a sensitivity of 87% (IQR = 80–91%) and a specificity of 87% (IQR = 80–91%) and for the best nondeconvolved measures TTP > 4.1 seconds (95% CI = 3.9–4.9) with a sensitivity of 85% (IQR = 77–90%) and a specificity of 85% (IQR = 77–90%; Table 3).
Discussion

This prospective imaging study of acute and subacute ischemic stroke was performed to improve mismatch-based tissue at risk detection and guide treatment decisions in ischemic stroke. To this end, we validated the whole range of established PW maps against full quantitative $^{15}$O-PET to determine the optimal PWI maps and thresholds to detect the penumbral flow threshold in ischemic stroke within 48 hours of symptom onset. The optimal PWI map and threshold that delineates penumbra from oligemia was identified using a voxel-based ROC curve analysis based on the classic PET penumbra definition of reduced blood flow (CBF) increased oxygen extraction (OEF) and stable oxygen metabolism (CMRO$_2$) in the gold standard PET group (group A) and the established PET penumbral flow threshold of reduced CBF in the larger PET group (group B).

Several novel findings, all with clear clinical implications, emerged from our gold standard PET group (group A) analysis: (1) the best PW parameter Tmax had an excellent threshold independent prediction of penumbral flow (AUC = 0.88), (2) the optimal penumbral flow threshold of the most predictive PW map Tmax > 5.6 seconds was highly accurate with a sensitivity and specificity above 80%, and (3) PW Tmax was highly reliable to identify the penumbral flow threshold up to 48 hours after stroke onset.

The current study has new important implications for mismatch detection in acute stroke, and several main issues need to be discussed. The threshold independent performance of PW Tmax was excellent with an AUC of 0.88. Tmax significantly outperformed other deconvolved and nondeconvolved measures (group A). The bigger PET-CBF group validation (group B) provides evidence that Tmax, TTP, and FM without DC are the best PWI parameters to detect the upper penumbral flow threshold. These results are roughly in line with those from the smaller full quantitative gold standard PET group (group A), which further strengthens the validity of our results and supports the use of deconvolved Tmax and nondeconvolved TTP if no AIF is used. These results are important because previous

| Patient ID | Site | Age, yr/Sex | NIHSS | Stroke to Imaging, h | MRI to PET, min | ICA/MCA Stenosis Ipsilateral, % | ICA/MCA Stenosis Contralateral, % | DWI Lesion, cm$^3$ | PET Penumbra, cm$^3$ |
|------------|------|-------------|-------|----------------------|-----------------|-------------------------------|-------------------------------|-----------------|-------------------|
| 1          | MCA R | 56/M        | 14    | 3                    | 111             | 0                             | 0                             | 9.3             | 18.3              |
| 2          | MCA R | 76/F        | 1     | 2.5                  | 210             | 100                           | 0                             | 10.1            | 186.7             |
| 3          | MCA L | 48/M        | 12    | 40                   | 271             | 0                             | 60                            | 17.4            | 208.3             |
| 4          | MCA L | 47/F        | 4     | 6                    | 120             | 100                           | 0                             | 7.7             | 10.9              |
| 5          | MCA R | 71/F        | 18    | 14                   | 57              | 0                             | 0                             | 20.1            | 129.4             |
| 6          | MCA L | 56/M        | 12    | 4.5                  | 150             | 100                           | 0                             | 96.2            | 145.0             |
| 7          | MCA L | 85/F        | 6     | 35                   | 102             | 0                             | 0                             | 40.4            | 23.5              |
| 8          | MCA R | 74/F        | 4     | 4                    | 100             | 60                            | 0                             | 25.0            | 47.7              |
| 9          | MCA R | 62/F        | 15    | 46                   | 127             | 90                            | 70                            | 21.6            | 42.0              |
| 10         | MCA L | 70/M        | 14    | 19                   | 100             | 100                           | 0                             | 24.8            | 164.1             |

Mean/median 65/66 10/12 17.4/10 135/116 — — —
Interquartile range 56–74 4–14 4–35 100–150 — — —
Minimum 47 1 2.5 57 — — —
Maximum 85 18 46 271 — — —

DWI = diffusion weighted lesions; F = female; ICA = internal carotid artery; ID = identification; L = left; M = male; MCA = middle cerebral artery; MRI = magnetic resonance imaging; NIHSS = National Institutes of Health Stroke Scale; PET = positron emission tomography; R = right.
validation studies in acute stroke showed conflicting results concerning the best PW parameter and threshold. Most previous studies validated PWI maps against a single quantitative PET or Xe-CT penumbra threshold (CBF < 20ml/100g/min). However, since the mismatch concept is a surrogate of the classic penumbra definition by PET,\(^2\)\(^3\) our study was particularly suitable to determine the best PW parameter to detect penumbra as defined by full quantitative PET. One reason why deconvolved Tmax detects the penumbral flow threshold with such a high accuracy might be the deconvolution procedure used for quantification, which, from a theoretical point of view, has advantages over

| PW Maps | AUC, Group A | AUC, Group B |
|---------|--------------|--------------|
| Tmax\(^a\) | 0.88 (0.78–0.91)\(^a\) | 0.94 (0.88–0.97)\(^b\) |
| CBF | 0.70 (0.64–0.85) | 0.84 (0.81–0.88) |
| CBV | 0.60 (0.56–0.67) | 0.65 (0.57–0.66) |
| MTT | 0.69 (0.62–0.79) | 0.81 (0.79–0.89) |
| TTP | 0.83 (0.74–0.88) | 0.93 (0.85–0.96)\(^b\) |
| BAT | 0.69 (0.67–0.73) | 0.82 (0.80–0.87) |
| BET | 0.65 (0.57–0.73) | 0.80 (0.71–0.84) |
| FWHM | 0.61 (0.60–0.68) | 0.65 (0.61–0.77) |
| FM without DC | 0.81 (0.74–0.87) | 0.89 (0.84–0.93)\(^b\) |
| FM with DC | 0.59 (0.57–0.71) | 0.61 (0.57–0.73) |
| Cmax | 0.66 (0.59–0.76) | 0.82 (0.79–0.89) |
| MS | 0.68 (0.59–0.72) | 0.80 (0.77–0.83) |
| CBV\(_\text{CTC}\) | 0.62 (0.56–0.74) | 0.72 (0.60–0.80) |
| dS/S | 0.65 (0.58–0.78) | 0.67 (0.59–0.79) |
| NEI | 0.64 (0.59–0.67) | 0.66 (0.61–0.69) |

Results are derived from the receiver operating characteristic curve analysis.

\(^a\)Significantly higher AUC values within group A.

\(^b\)Significantly higher AUC values within group B. Repeated measures analysis of variance on ranks and post hoc analysis Student-Newman-Keuls procedure for multiple comparisons at a corrected type I error level of 0.05.

Median values of the AUC values. Variation is stated as interquartile range.

AUC = area under the curve; BAT = bolus arrival time; BET = bolus end time; CBF = cerebral blood flow; CBV = cerebral blood volume; CBV\(_\text{CTC}\) = cerebral blood volume of the tissue contrast concentration time curve; Cmax = maximum of the concentration time curve; CMRO\(_2\) = cerebral metabolic rate of oxygen; DC = delay correction; dS/S = normalized signal drop; FM = first moment; FWHM = full width at half maximum; MS = maximum slope; MTT = mean transit time; NEI = negative enhancement integral; OEF = oxygen extraction fraction; PET = positron emission tomography; PW = perfusion weighted; Tmax = time to maximum; TTP = time to peak.
nondeconvolved measures (eg, TTP, FM). Deconvolution might therefore help to detect tissue that is affected by not only low blood flow but also compromised oxygen metabolism. For a thorough discussion of deconvolution, see Reimer and colleagues.18 Tmax performs better than physiologic PWI maps because Tmax calculation is only dependent on the tissue response curve to its peak and not on the whole response curve like many other maps (eg, CBV, MTT, FM), making Tmax also less prone to artifacts.19,35 The accuracy to detect penumbral flow thresholds with PW measures shows slightly lower AUC values if validated against the classical PET definition of penumbra (group A) rather than against a single PET perfusion CBF threshold (group B); Tmax AUC = 0.88 vs 0.94. This might be attributed to PWI being a surrogate of blood flow, and a direct comparison to PET-based blood flow without metabolic measures is more straightforward. However, our validation based on full quantitative PET (group A) might well provide a more accurate performance of PWI penumbral flow detection.

The optimal penumbral threshold to distinguish penumbral from oligemic tissue is Tmax > 5.6 seconds. Along with the optimal thresholds for TTP > 3.8 seconds, our results are in line with the results of group B and some previous comparative PET–Xe-CT–, and MR-based studies.19,36,41 However, we found a slightly lower optimal TTP threshold than some previous studies.19,36,42,43 This might be due to the classic PET definition of penumbra used for PWI validation leading to further improved optimal penumbral thresholds. We also performed a voxelwise ROC curve analysis rather than a ROI-based analysis, which might lead to less biased thresholds.

Because patients in this study exhibited penumbral tissue up to 48 hours after stroke onset, we could prove for the first time that the performance of the PWI parameter Tmax > 5.6 seconds is excellent in detecting the upper penumbral flow threshold up to 48 hours after stroke onset. This time window is in line with previous PET-based studies, which detected penumbral tissue with 15O-PET as late as 18 to 48 hours4,10 and with 18F-fluoromisonidazole PET as late as 48 hours.44

Few previous studies have validated the mismatch concept in acute and subacute ischemic stroke. There have been 2 different approaches to validate the performance of established PWI maps to detect penumbral flow: MR-based validation studies compare PWI maps with infarct growth on late MRI as a reference in patients without reperfusion. These studies either compare the performance of different PWI maps35,45,46 or identify the optimal perfusion threshold of a single PWI map43,47 to detect penumbral tissue. It is crucial in these MR-based validations to exclude reperfusers. Therefore, these studies only included patients without thrombolytic therapy43,45,47,48 or patients with proven nonreperfusion.35 In addition, the optimal imaging method and time to accurately detect the final infarct is of importance.49 These studies investigated different PWI maps and found different results in terms of the best PWI map and threshold to detect tissue at risk of infarction. Some variation in results might be explained by methodological differences of how reperfusers were excluded and how final infarct was defined.

PET or Xe-CT–based studies compare PWI maps back to back with a measure of quantitative CBF, for example, PET19,36,42 or Xe-CT.41 In these studies, the best PWI maps and thresholds are validated against CBF < 20ml/100g/min, which is used to discriminate oligemic from penumbral tissue.23 Previous studies of our group found

---

### TABLE 3. Optimal Penumbral Flow Threshold Values (Median) of Group A (PET-CBF, -OEF, -CMRO2) and Group B (PET-CBF) for the Best Deconvolved Tmax and Nondeconvolved TTP Perfusion Maps

| PW Maps | PF Threshold, s* | Sensitivity, % | Specificity, % |
|---------|------------------|----------------|---------------|
| Group A |                  |                |               |
| Tmax    | >5.6 (95% CI = 4.6–6.1) | 81 (IQR = 70–83) | 81 (IQR = 71–83) |
| TTP     | >3.8 (95% CI = 3.7–4.4) | 77 (IQR = 68–81) | 77 (IQR = 67–82) |
| Group B |                  |                |               |
| Tmax    | >6.0 (95% CI = 4.9–6.9) | 87 (IQR = 80–91) | 87 (IQR = 80–91) |
| TTP     | >4.1 (95% CI = 3.9–4.9) | 85 (IQR = 77–90) | 85 (IQR = 77–90) |

Results are derived from the receiver operating characteristic curve analysis. PF threshold is defined by the ESST.

*C, bootstrap 95% CI (1,000 iterations; random number seed = 978).

CBF = cerebral blood flow; CI = confidence interval; CMRO2 = cerebral metabolic rate of oxygen; ESST = penumbral flow threshold corresponding to the equal sensitivity and specificity threshold; OEF = oxygen extraction fraction; PET = positron emission tomography; PF threshold = optimal penumbral flow threshold; PW = perfusion weighted; Tmax = time to maximum; TTP = time to peak.
deconvolved Tmax > 6.1 seconds and nondeconvolved TTP > 4.2 seconds, Cmax < 0.66, and FM without DC > 3.6 seconds to perform best and equally well in discriminating tissue with PET CBF < 20ml/100g/min. However, these studies did not validate PW maps against penumbra as defined by full quantitative 15O-PET. Another study of 5 acute and subacute stroke patients investigated the performance of PW maps (Tmax > 5.5 seconds, MTT > 6 seconds, TTP > 4.8 seconds) to detect penumbral flow thresholds against quantitative and full quantitative 15O-PET and found no difference in performance.36 Olivot and colleagues41 validated Tmax and MTT in 7 subacute stroke patients against Xe-CT and found Tmax > 4 seconds to be more reliable than MTT > 10 seconds to detect critical hypoperfusion.

In summary, previous MR-, PET- and Xe-CT-based validation studies found conflicting results as to which PW map and threshold performs best in detecting penumbral tissue. To settle the dispute, we validated all established PW maps against the classical penumbra definition of full quantitative PET up to 48 hours after stroke and provide
clear recommendations to the clinician in terms of the best PW map and its optimal threshold.

From a clinical point of view, these results are important because the optimal PW maps and penumbra thresholds validated against full quantitative PET up to 48 hours of stroke onset are pivotal to detect penumbral tissue and can help the clinician to decide on revascularization or other options of treatment in acute stroke beyond the established time windows. This is particularly true because recent clinical stroke studies (DEFUSE-3 and DAWN)\textsuperscript{16,17} have shown a clinical benefit of endovascular revascularization based on mismatch detection within 24 hours of stroke onset.

Several methodological issues need to be discussed. First, we validated the whole range of PW maps against full quantitative \(^{15}\text{O}\)-PET and processed these maps with a validated software (PMA) which allows calculation of a wide range of deconvolved and nondeconvolved PW maps with high precision.\textsuperscript{31} Second, our validation was performed using a voxel-based ROC-curve analysis, which allows an unbiased approach to detect the most predictive PW maps and their optimal thresholds.\textsuperscript{35} Third, because we wanted the sensitivity and specificity to be equal for optimal penumbral flow threshold definition, the best cutoff threshold using the ROC curve analysis was determined by the ESST.\textsuperscript{35} However, depending on the individual clinical setting, a higher sensitivity or specificity might be required and the optimal threshold values might be different. Fourth, the PWI-based penumbral flow thresholds are valid for grey matter only, and the inclusion of white matter may lead to slightly higher (eg, Tmax) or lower (eg, CBF) PWI penumbra thresholds. We minimized this error by creating a grey matter mask that excluded white matter voxels. Therefore, the results are not applicable to pure subcortical infarcts. Fifth, we validate the upper limit of penumbral flow (ie, discrimination of penumbral from oligemic flow). This is a standard approach,\textsuperscript{35,36,41} because the lower limit of penumbral flow (ie, the infarct core threshold) is defined by the DWI lesion within the mismatch concept and has previously been validated by \(^{11}\text{C}\)-flumazenil PET.\textsuperscript{50,51} Sixth, we present the biggest patient sample of full quantitative \(^{15}\text{O}\)-PET with continuous PW MR in acute stroke. The restricted numbers in the literature are due to the very challenging logistics to perform these measures in acute stroke (see Patients and Methods section). However, our bigger PET-CBF group validation (group B) shows time-driven parameters to perform best, which strengthens the results of the gold standard PET group (group A). Seventh, the time of stroke onset to imaging does not influence the validity of our results because the upper CBF “penumbra” threshold is, unlike the lower CBF “infarction” threshold, not time dependent.\textsuperscript{1,52} Eighth, the brief inhalation \(^{15}\text{O}\)-PET method used in this study can be used for full quantitative regional measurement of CBF, OEF, and CMRO\textsubscript{2}. It has been fully validated for a wide range of values and is valid for low blood flow values under pathologic conditions such as stroke.\textsuperscript{25,53} The main advantage of the brief inhalation method is that it is a rapid technique, is easy to repeat, and involves a lower radiation dosage. It is less time consuming than the steady-state \(^{15}\text{O}\)-PET method, and less patient cooperation is needed, which is, along with the shorter scanning procedure, an advantage in stroke patients.\textsuperscript{54} Ninth, flow and metabolic changes during consecutive MR and PET imaging were minimized by keeping the time between both imaging modalities as short as possible, excluding patients with revascularization treatment and clinical changes (NIHSS > 2 points) during and between imaging. We also monitored CBF by sonography of the cerebral arteries before and between the scans. However, to eliminate changes between MR and PET completely, imaging should be performed simultaneously on a PET/MR hybrid scanner in future studies. Tenth, PWI maps showed an individual variation of the optimal penumbral flow threshold despite the use of deconvolution algorithms based on input functions in deconvolved PWI or normalization to the contralateral nonaffected hemisphere in nondeconvolved PWI. The use of quantitative bookend DSC-MR in future studies might reduce this individual over- or underestimation of penumbral tissue.\textsuperscript{55} Eleventh, because the classical PET-based definition of penumbra is based on CBF, OEF, and CMRO\textsubscript{2}, mismatch-based penumbral tissue detection in acute stroke might benefit from additional validated MR-based quantitative measures of OEF and oxygen metabolism (CMRO\textsubscript{2}).\textsuperscript{56}

In summary, this study of acute and subacute ischemic stroke validated a wide range of established PW parameters against the classical definition of penumbra as defined by full quantitative \(^{15}\text{O}\)-PET within 48 hours of stroke onset. We demonstrated that Tmax > 5.6 seconds is outstanding in detecting the upper penumbral flow threshold up to 48 hours after stroke onset and outperforms other PWI parameters. However, if no selection of an AIF is feasible, nondeconvolved TTP > 3.8 seconds is a very good alternative to Tmax. These results might help to expand acute stroke treatment well beyond the current time windows.

**Acknowledgment**

The research leading to these results received funding from the Max Planck Society and the Boll Foundation. This work was also funded by the Center for Stroke Research Berlin grant (01EO 0801 and 01EO 01301)
from the German Federal Ministry of Education and Research. The funding bodies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

We thank the members of the neurocritical care unit (Department of Neurology), the staff of the MRI facility (Department of Neuroradiology), and especially the staff of the PET unit (Max-Planck-Institute for Neurological Research) for helpful cooperation in this multimodal imaging study.

**Author Contributions**

O.Z.W., H.F., L.R., and W.D.H. contributed to the study concept and design. O.Z.W., H.F., L.R., A.S., and W.M.H. contributed to data acquisition and analysis. O.Z.W., H.F., and L.R. contributed to drafting of the manuscript and figures. All authors revised the manuscript critically for important intellectual content and approved the final version.

**Potential Conflicts of Interest**

Nothing to report.

**References**

1. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia — the ischemic penumbra. Stroke 1981;12:723–725.
2. Baron JC. Mapping the ischaemic penumbra with PET: implications for acute stroke treatment. Cerebrovasc Dis 1999;9:193–201.
3. Heiss WD. Ischemic penumbra: evidence from functional imaging in man. J Cereb Blood Flow Metab 2000;20:1276–1293.
4. Heiss WD, Huber M, Fink GR, et al. Progressive derangement of perfusion and viable tissue in ischemic stroke. J Cereb Blood Flow Metab 1992;12:193–203.
5. Hossmann KA. Viability thresholds and the penumbra of focal ischaemia. Ann Neurol 1994;36:557–565.
6. Ackerman RH, Correa JA, Alpert NM, et al. Positron imaging in ischemic stroke disease using compounds labeled with oxygen 15. Initial results of clinicophysiological correlations. Arch Neurol 1981;38:537–543.
7. Lenzi GL, Frackowiak RS, Jones T. Cerebral oxygen metabolism and blood flow in human cerebral ischemic infarction. J Cereb Blood Flow Metab 1982;2:321–335.
8. Powers WJ, Grubb RL Jr, Darriet D, Raichle ME. Cerebral blood flow and cerebral metabolic rate of oxygen requirements for cerebral function and viability in humans. J Cereb Blood Flow Metab 1985;S:600–608.
9. Wise RJ, Bernardi S, Frackowiak RS, Legg NJ, Jones T. Serial observations on the pathophysiology of acute stroke. The transition from ischaemia to infarction as reflected in regional oxygen extraction. Brain 1983;106(pt 1):197–222.
10. Marchal G, Beaudouin V, Rioux P, et al. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: a correlatve PET-CT study with voxel-based data analysis. Stroke 1996;27:599–606.
11. Baron JC, Bousser MG, Comar D, Soussaline F, Castaigne P. Noninvasive tomographic study of cerebral blood flow and oxygen metabolism in vivo. Potentials, limitations, and clinical applications in cerebral ischemic disorders. Eur Neurol 1981;20:273–284.
12. Warach S, Dashe JF, Edelman RR. Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion magnetic resonance imaging: a preliminary analysis. J Cereb Blood Flow Metab 1996;16:53–59.
13. Sorensen AG, Buonanno FS, Gonzalez RG, et al. Hyperacute stroke: evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging. Radiology 1996;199:391–401.
14. Schlaug G, Benfield A, Baird AE, et al. The ischemic penumbra: operationally defined by diffusion and perfusion MRI. Neurology 1999;53:1528–1537.
15. Sabesky J. Refining the mismatch concept in acute stroke: lessons learned from PET and MRI. J Cereb Blood Flow Metab 2012;32:1416–1425.
16. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 2018;378:708–718.
17. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018;378:11–21.
18. Reimer J, Montag C, Schuster A, et al. Is Perfusion MRI without deconvolution reliable for mismatch detection in acute stroke? Validation with 15O-posietron emission tomography. Cerebrovasc Dis 2018;46:16–23.
19. Zaro-Weber O, Moeller-Hartmann W, Siegmund D, et al. MRI-based mismatch detection in acute ischemic stroke: optimal PWI maps and thresholds validated with PET. J Cereb Blood Flow Metab 2017;37:3176–3183.
20. Zaro-Weber O, Livne M, Martin SZ, et al. Comparison of the 2 most popular deconvolution techniques for the detection of penumbral flow in acute stroke. Stroke 2015;46:2795–2799.
21. Zaro-Weber O, Moeller-Hartmann W, Heiss WD, Sabesky J. Influence of the arterial input function on absolute and relative perfusion-weighted imaging penumbral flow detection: a validation with 15O-water positron emission tomography. Stroke 2012;43:378–385.
22. Zaro-Weber O, Moeller-Hartmann W, Heiss WD, Sabesky J. The performance of MRI-based cerebral blood flow measurements in acute and subacute stroke compared with 15O-water positron emission tomography: identification of penumbral flow. Stroke 2009;40:2413–2421.
23. Zaro-Weber O, Moeller-Hartmann W, Heiss WD, Sabesky J. Maps of time to maximum and time to peak for mismatch detection in clinical stroke studies validated with positron emission tomography. Stroke 2010;41:2817–2821.
24. Wienthard K, Dahlborn M, Eriksson L, et al. The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994;18:110–118.
25. Mintun MA, Raichle ME, Martin WR, Herscovitch P. Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. J Nucl Med 1984;25:177–187.
26. Raichle ME, Martin WR, Herscovitch P, Mintun MA, Markham J. Brain blood flow measured with intravenous H2(15)O; II. Implementation and validation. J Nucl Med 1983;24:790–798.
27. Martin WR, Powers WJ, Raichle ME. Cerebral blood volume measured with inhaled C15O and positron emission tomography. J Cereb Blood Flow Metab 1987;7:421–426.
28. Eriksson L, Holte S, Bohm C, Kesselberg M, Hovander B. Automated blood sampling system for positron emission tomography. IEEE Trans Nucl Sci 1988;35:703–707.
29. Sobesky J, Zaro-Weber O, Lehnhardt FG, et al. Does the mismatch match the penumbra? Magnetic resonance imaging and positron emission tomography in early ischemic stroke. Stroke 2005;36:980–985.

30. Cizek J, Herholz K, Vollmar S, Schrader R, Klein J, Heiss WD. Fast and robust registration of PET and MR images of human brain. Neuroimage 2004;22:434–442.

31. Kudo K, Christensen S, Sasaki M, et al. Accuracy and reliability assessment of CT and MR perfusion analysis software using a digital phantom. Radiology 2013;267:201–211.

32. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med 1996;36:715–725.

33. Leiva-Salinas C, Provenzale JM, Kudo K, Sasaki M, Wintermark M. The alphabet soup of perfusion CT and MR imaging: terminology revisited and clarified in five questions. Neuroradiology 2012;54:907–918.

34. Perthen JE, Calamante F, Gadian DG, Connelly A. Is quantification of bolus tracking MRI reliable without deconvolution? Magn Reson Med 2002;47:61–67.

35. Christensen S, Mouridsen K, Wu O, et al. Comparison of 10 perfusion MRI parameters in 97 sub-6-hour stroke patients using voxel-based receiver operating characteristics analysis. Stroke 2009;40:2055–2061.

36. Takasawa M, Jones PS, Guadagno JV, et al. How reliable is perfusion MR in acute stroke? Validation and determination of the penumbra threshold against quantitative PET. Stroke 2008;39:870–877.

37. Butcher KS, Parsons M, MacGregor L, et al. Refining the perfusion-diffusion mismatch hypothesis. Stroke 2005;36:1153–1159.

38. Furlan M, Marchal G, Viader F, Derlon JM, Baron JC. Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol 1996;40:216–226.

39. Baron JC, Rougemont D, Soussaline F, et al. Local interrelationships of cerebral oxygen consumption and glucose utilization in normal subjects and in ischemic stroke patients: a positron tomography study. J Cereb Blood Flow Metab 1984;4:140–149.

40. Efron B. Better bootstrap confidence intervals. Journal of the American Statistical Association 1987;82(397):171–185.

41. Oliivot JM, Mlynash M, Zaharchuk G, et al. Perfusion MRI (Tmax and MTT) correlation with xenon CT cerebral blood flow in stroke patients. Neurology 2009;72:1140–1145.

42. Sobesky J, Zaro-Weber O, Lehnhardt FG, et al. Which time-to-peak threshold best identifies penumbral flow? A comparison of perfusion-weighted magnetic resonance imaging and positron emission tomography in acute ischemic stroke. Stroke 2004;35:2843–2847.

43. Neumann-Haefelin T, Wittsack HJ, Wenserski F, et al. Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute stroke. Stroke 1999;30:1591–1597.

44. Read SJ, Hirano T, Abbott DF, et al. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole. Neurology 1998;51:1617–1621.

45. Grandin CB, Duprez TP, Smith AM, et al. Which MR-derived perfusion parameters are the best predictors of infarct growth in hyperacute stroke? Comparative study between relative and quantitative measurements. Radiology 2002;223:361–370.

46. Rohl L, Geday J, Ostergaard L, et al. Correlation between diffusion- and perfusion-weighted MRI and neurological deficit measured by the Scandinavian Stroke Scale and Barthel Index in hyperacute subcortical stroke (< or = 6 hour). Cerebrovasc Dis 2001;12:203–213.

47. Parsons MW, Yang Q, Barber PA, et al. Perfusion magnetic resonance imaging maps in hyperacute stroke: relative cerebral blood flow most accurately identifies tissue destined to infarct. Stroke 2001;32:1581–1587.

48. Rohl L, Ostergaard L, Simonsen CZ, et al. Viability thresholds of ischemic penumbra of hyperacute stroke defined by perfusion-weighted MRI and apparent diffusion coefficient. Stroke 2001;32:1140–1146.

49. Lansberg MG, O’Brien MW, Tong DC, Moseley ME, Albers GW. Evolution of cerebral infarct volume assessed by diffusion-weighted magnetic resonance imaging. Arch Neurol 2001;58:613–617.

50. Heiss WD, Sobesky J, Smekal U, et al. Viability thresholds of hypoxic tissue after a brief subtherapeutic focal ischemia in awake monkeys. J Neurosurg 1981;54:773–782.

51. Guadagno JV, Warburton EA, Jones PS, et al. How affected is oxygen metabolism in DWI lesions?: A combined acute stroke PET-MR study. Neurology 2006;67:824–829.

52. Jones TH, Morawetz RB, Crowell RM, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 1981;54:773–782.

53. Altman DI, Lich LL, Powers WJ, et al. Brief inhalation method to measure cerebral oxygen extraction fraction with PET. accuracy determination under pathologic conditions. J Nucl Med 1991;32:1738–1741.

54. Baron JC, Frackowiak RS, Herholz K, et al. Use of PET methods for measurement of cerebral energy metabolism and hemodynamics in cerebrovascular disease. J Cereb Blood Flow Metab 1989;9:723–742.

55. Smro JM, Shin W, Shah S, Sen A, Carroll TJ. SCALE-PWI: a pulse sequence for absolute quantitative cerebral perfusion imaging. J Cereb Blood Flow Metab 2011;31:1272–1282.

56. Lin W, Powers WJ. Oxygen metabolism in acute ischemic stroke. J Cereb Blood Flow Metab 2018;38:1481–1499.